Morgan Stanley Maintains Overweight on Trevi Therapeutics, Lowers Price Target to $18
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Morgan Stanley analyst Judah Frommer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and lowers the price target from $19 to $18.
Morgan Stanley analyst Judah Frommer maintains Trevi Therapeutics (NASDAQ:TRVI) with a Overweight and lowers the price target from $19 to $18.